Immuno-oncology company Agenus Inc (NASDAQ:AGEN) on Monday announced that Incyte has made a cash milestone payment of USD5m for the initiation of its Phase 1 clinical trial of INCAGN2385.
INCAGN2385 is reportedly an anti-LAG-3 antibody discovered by Agenus under its partnered programme with Incyte, a biopharmaceutical research company.
Based on this milestone agreement, Agenus is eligible to receive up to another USD505m in potential development, regulatory and commercial milestones from Incyte.
Under the terms of the agreement, Incyte has exclusive rights to fund and conduct global development and commercialisation of four disclosed antibody candidates, LAG-3, TIM-3, GITR and OX40 and one undisclosed candidate, under which, Agenus is eligible to receive milestone and royalty payments.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval